Exploring the Etiological Overlap between Parkinson's Disease and Multiple Sclerosis: A Novel Avenue for Treating MS
Biomedical Research and Clinical Reviews · 12.06.2023 · 08 (02) · 01-04
DOI: 10.31579/2692-9406/151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Research and Clinical Reviews, online erschienen am 12.06.2023. Verfasst von Ahed J Alkhatib.
Abstract (Originalsprache)
After many years of monotherapy with ursodeoxycholic acid and many reports of its long-term benefits, mostly positive the physician now has an opportunity to consider the use of newer medications. However, the decision to choose a newer medication is biased in favor of ursodeoxycholic acid because it is viewed as the ““gold standard” implying that other medications will always have a secondary role. A major threat to the patient’s well-being is persisting with this approach and the failure to recognize in a timely manner that ursodeoxycholic acid is causing liver injury. Very rarely toxicity is apparent within a few weeks of administration.
Zitieren
APA
Alkhatib, A. J. (2023). Exploring the Etiological Overlap between Parkinson's Disease and Multiple Sclerosis: A Novel Avenue for Treating MS. Biomedical Research and Clinical Reviews, 08(02), 01-04. https://doi.org/10.31579/2692-9406/151
Vancouver
Alkhatib AJ. Exploring the Etiological Overlap between Parkinson's Disease and Multiple Sclerosis: A Novel Avenue for Treating MS. Biomedical Research and Clinical Reviews. 2023;08(02):01-04. doi:10.31579/2692-9406/151
BibTeX
@article{Alkhatib2023,
author = {Alkhatib, Ahed J},
title = {Exploring the Etiological Overlap between Parkinson's Disease and Multiple Sclerosis: A Novel Avenue for Treating MS},
journal = {Biomedical Research and Clinical Reviews},
year = {2023},
volume = {08},
number = {02},
pages = {01--04},
doi = {10.31579/2692-9406/151}
}
EUVIMED